CTX-471 + Trastuzumab
and/or Cetuximab

Currently evaluating pre-clinical efficacy of CTX-471 in combination with tumor targeting antigen antibodies on the market including, trastuzumab, marketed as Herceptin®. by Genentech, in selected Her2+ tumors and cetuximab, marketed as Erbitux® by Lilly, in EGFR+ tumors.